Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate
Public ClinicalTrials.gov record NCT00903383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-center, Randomized, Double Blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX3305 versus a placebo control in subjects with active rheumatoid arthritis on stable methotrexate therapy.
Study identification
- NCT ID
- NCT00903383
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2009
- Primary completion
- Aug 31, 2010
- Completion
- Not listed
- Last update posted
- Dec 14, 2011
Started 2009
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lexicon Investigational Site | Gainesville | Florida | 32607 | — |
| Lexicon Investigational Site | Orange Park | Florida | 32073 | — |
| Lexicon Investigational Site | Orlando | Florida | 32804 | — |
| Lexicon Investigational Site | Tampa | Florida | 33614 | — |
| Lexicon Investigational Site | Cumberland | Maryland | 21502 | — |
| Lexicon Investigational Site | Hagerstown | Maryland | 21740 | — |
| Lexicon Investigational Site | Kalamazoo | Michigan | 49009 | — |
| Lexicon Investigational Site | Flowood | Mississippi | 39232 | — |
| Lexicon Investigational Site | Hickory | North Carolina | 28601 | — |
| Lexicon Investigational Site | Philadelphia | Pennsylvania | 19152 | — |
| Lexicon Investigational Site | Nashville | Tennessee | 37205 | — |
| Lexicon Investigational Site | Dallas | Texas | 75235 | — |
| Lexicon Investigational Site | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00903383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2011 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00903383 live on ClinicalTrials.gov.